Effect of Nirmatrelvir/Ritonavir (Paxlovid) on Hospitalization among Adults with COVID-19: an EHR-based Target Trial Emulation from N3C

Abhishek Bhatia, Alexander J. Preiss, Xuya Xiao, M. Daniel Brannock, G. Caleb Alexander, Robert F. Chew, Megan Fitzgerald, Elaine Hill, Elizabeth P. Kelly, Hemalkumar B. Mehta, Charisse Madlock-Brown, Kenneth J. Wilkins, Christopher G. Chute, Melissa Haendel, Richard Moffitt, Emily R. Pfaff, The N3C Consortium
doi: https://doi.org/10.1101/2023.05.03.23289084

Article usage

Article usage: May 2023 to December 2024

AbstractFullPdf
May 202370232169
Jun 20231894255
Jul 20231243149
Aug 20231064664
Sep 2023742946
Oct 2023782748
Nov 20231031631
Dec 202362529
Jan 2024731031
Feb 202435418
Mar 202466432
Apr 202451927
May 2024611039
Jun 202458441
Jul 202461651
Aug 202466731
Sep 202456926
Oct 202455320
Nov 202449628
Dec 202415310
Back to top
Posted May 04, 2023.
Download PDF
Data/Code
Email
Effect of Nirmatrelvir/Ritonavir (Paxlovid) on Hospitalization among Adults with COVID-19: an EHR-based Target Trial Emulation from N3C
Abhishek Bhatia, Alexander J. Preiss, Xuya Xiao, M. Daniel Brannock, G. Caleb Alexander, Robert F. Chew, Megan Fitzgerald, Elaine Hill, Elizabeth P. Kelly, Hemalkumar B. Mehta, Charisse Madlock-Brown, Kenneth J. Wilkins, Christopher G. Chute, Melissa Haendel, Richard Moffitt, Emily R. Pfaff, The N3C Consortium
medRxiv 2023.05.03.23289084; doi: https://doi.org/10.1101/2023.05.03.23289084
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area